TrialHormones & cancer2014
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Antonio M Lerario et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
53 papers cite it
this paperpooled ittrialcites it